Related resources and publications
![](https://cdn.prod.website-files.com/655dd3c88278aa64954052d4/667c0461fb2f58fb8d6d4247_maxivax-poster-aacr2023-ctla-4_preview.webp)
CTLA-4 & survival in a colorectal cancer model
The humanized CTLA‑4 mouse model (hCTLA-4) is developed by Knockin at the mouse CTLA‑4 locus, and enables the expression of: a) the full-length chimeric CTLA-4 isoform; and b) the soluble isoform.
The design also gives access to CTLA-4 conditional Knockout mice for a tissue-specific assessment of compounds’ specificity and toxicity.
hCTLA-4 and mCTLA-4 expression on αCD3-activated splenocytes on A) Tregs (viable, CD3+CD4+CD25+Foxp3+), B) conventional CD4+ (viable, CD3+CD4+Foxp3-) at day 3, and C) CD8+ (viable, CD3+CD8+) T cells at indicated time points.
Wild-type and hCTLA-4 mice were implanted s.c. with MC38 tumor on day 0 with n=10 mice per group. Survival of mice treated with αhCTLA-4 (ipilimumab), αmCTLA-4 (9H10) or isotype i.p. bi-weekly for 4 weeks.
(Mantel-Cox test: ****p<0.0001)
CTLA-4 & survival in a colorectal cancer model
Let us know how we can help
Physiological relevance
Comprehensive and reliable validation data
Over 600 scientific articles based on our models
In-depth expertise in preclinical science, physiology, and model development
Unique R&D platform located in France
Tailor-made approach to your needs
Strong emphasis on customer satisfaction
Long-standing partnerships with 17 of the top 20 pharma companies
Co-development of innovative models for next-generation drugs
Guaranteed FTO/freedom to operate